Beijing Science Sun Pharmaceutical Co., Ltd. (300485) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Beijing Science Sun Pharmaceutical Co., Ltd.

Why is Beijing Science Sun Pharmaceutical Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 2.69%

The company has been able to generate a Return on Capital Employed (avg) of 2.69% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of -18.31% and Operating profit at -144.79% over the last 5 years

Flat results in Sep 25

OPERATING PROFIT(Q) Lowest at CNY -11.68 MM
OPERATING PROFIT MARGIN(Q) Lowest at -10.45 %
PRE-TAX PROFIT(Q) Lowest at CNY -1.94 MM

With ROE of 0.75%, it has a fair valuation with a 1.60 Price to Book Value

Over the past year, while the stock has generated a return of 46.55%, its profits have risen by 126.8% ; the PEG ratio of the company is 1.7

Market Beating Performance

The stock has generated a return of 46.55% in the last 1 year, much higher than market (China Shanghai Composite) returns of 15.17%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Beijing Science Sun Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Beijing Science Sun Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Beijing Science Sun Pharmaceutical Co., Ltd.

46.48%

0.91

65.43%

China Shanghai Composite

15.17%

1.02

14.86%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-18.31%

EBIT Growth (5y)

-144.79%

EBIT to Interest (avg)

40.84

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.47

Sales to Capital Employed (avg)

0.13

Tax Ratio

23.40%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

2.69%

ROE (avg)

3.20%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

214

Industry P/E

Price to Book Value

1.60

EV to EBIT

218.12

EV to EBITDA

59.38

EV to Capital Employed

2.15

EV to Sales

9.77

PEG Ratio

1.68

Dividend Yield

ROCE (Latest)

0.98%

ROE (Latest)

0.75%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

DEBT-EQUITY RATIO (HY)

Lowest at -47.97 %

RAW MATERIAL COST(Y)

Fallen by -7.2% (YoY

NET PROFIT(9M)

Higher at CNY 22.47 MM

CASH AND EQV(HY)

Highest at CNY 3,283.09 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 1.84 times

NET SALES(Q)

Highest at CNY 111.83 MM

-12What is not working for the Company

OPERATING PROFIT(Q)

Lowest at CNY -11.68 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -10.45 %

PRE-TAX PROFIT(Q)

Lowest at CNY -1.94 MM

NET PROFIT(Q)

At CNY 5 MM has Fallen at -38.3%

EPS(Q)

Lowest at CNY 0.01

Here's what is working for Beijing Science Sun Pharmaceutical Co., Ltd.

Debt-Equity Ratio

Lowest at -47.97 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Sales

Highest at CNY 111.83 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Cash and Eqv

Highest at CNY 3,283.09 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio

Highest at 1.84 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -7.2% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Beijing Science Sun Pharmaceutical Co., Ltd.

Pre-Tax Profit

At CNY -1.94 MM has Fallen at -142.69%

over average net sales of the previous four periods of CNY 4.54 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Operating Profit

Lowest at CNY -11.68 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at -10.45 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at CNY -1.94 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 5 MM has Fallen at -38.3%

over average net sales of the previous four periods of CNY 8.11 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

EPS

Lowest at CNY 0.01

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CNY)